Join us at JPM26 in SF + online Jan 12-13

‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌

No images? Click here

Endpoints at JPM26: Biopharma's Foundational Reset

Beyond the talking points:
Endpoints at JPM

JANUARY 12 - 13, 2026 | 7:00 AM - 5:00 PM PT
MARRIOTT MARQUIS, SAN FRANCISCO | HYBRID

The biopharma money has dried up, but the deals haven't stopped — they've just gotten harder. As the industry gathers in San Francisco for JPM, everyone's asking the same question: What actually works when capital is scarce and the old playbook is dead? 

Join Endpoints in SF — we're inviting you to the center of the action. Get the deep dive on JPM Monday and Tuesday, with real conversations from the leaders shaping biopharma's future. Need to work? The Endpoints Hub offers a premium coworking lounge, a place to escape the noise, compare notes with peers who get it, and figure out your next move over breakfast, lunch, and real conversation.

CHOOSE YOUR PASS

 Use code JPM26_LO to save on your in-person pass.

ALL-ACCESS

Join us in-person on Monday & Tuesday  

DAY PASS

Join us in-person on Monday or Tuesday  

GROUP PASS

Includes 3 All-Access passes

Can't make it in person? Join us virtually for free.

The story behind the deals happening right now

John Carroll sits down with dealmakers from Amgen, PwC, and AbbVie to discuss the M&A surge that delivered multiple $10 billion acquisitions despite the broader downturn. They'll examine whether this momentum continues into 2026 or if buyers pull back. Which biotechs will survive, and which will become the next targets?

The executives steering biopharma through its toughest period are ready to share what they're seeing. Mike Doustdar, CEO of Novo Nordisk, took the helm as the obesity market Novo pioneered became increasingly competitive. After several months leading the Danish giant, he's sitting down with Drew Armstrong to discuss his vision for reclaiming Novo's edge.

View the full agenda here.

Mike Doustdar
CEO, Novo Nordisk

  • Save 15% when you buy a group pass — plus you can assign names later on for your team

  • Virtual passes are available at no charge
 
RESERVE YOUR SPOT

Use code JPM26_LO to save on your in-person pass

RECENTLY ADDED: NETWORKING. INSIGHT.
A LIVE PODCAST TAPING. YOU IN?

In-person passes include access to our invite-only networking reception on Tuesday, Jan. 13, featuring drinks, light bites, and a live taping of Post-hoc Live with Executive Editor Drew Armstrong and special guest Noubar Afeyan, Founder and CEO of Flagship Pioneering. 

Join fellow passholders, industry peers, and Endpoints editors to debrief the week and connect before heading out.

Reserve your in-person pass to Endpoints at JPM to receive your reception invitation. Space is limited — RSVP required.

 

EVENT SPONSORS

Vir Biotechnology
 
Catalent
 
FUJIFILM Biotechnologies
Biocon Biologics
pwc
Tarsus Pharmaceuticals
Foundation Medicine
GILEAD
Slalom and Salesforce
 
Cencora